The company’s first solution utilizing the BioWick technology is designed to address the biology issue associated with rotator cuff repair failures.

The BioWick™ SureLock™ Implant, an interpositional scaffold wick, is deployed arthroscopically between tendon and bone, allowing surgeons to maintain their current standard technique while reducing bone removal through a smaller pilot hole.

The implant will be debuted at the 2016 American Academy of Orthopaedic Surgeons Annual Meeting (AAOS), March 2-4, Orlando, Florida at booth #2809.

"The BioWick™ platform is a continuation of Cayenne Medical’s philosophy of innovation to address significant unmet clinical needs while saving procedure time and being cost effective," stated Dave Springer, President and CEO of Cayenne Medical. "We believe our differentiated design supported by statistically significant animal data will provide the most integrated approach in addressing the large failure rate with initial rotator cuff repairs."

Cayenne Medical’s multi-year development for this new technology is supported by strong, statistically significant results in a GLP sheep study conducted at Colorado State University. The company believes this comprehensive data, combined with the implant’s ease of delivery, addresses a true unmet need in the market.

Mark Frankle, MD, of the Florida Orthopaedic Institute in Tampa, is one of several early implanters of the product. "The BioWick™ technology is an exciting innovation supported by robust scientific evidence that allows me to use my same surgical techniques for rotator cuff repair."

The BioWick™ scaffold wick is composed of aligned, PLGA microfibers designed to mimic the extracellular matrix (ECM) of the rotator cuff tendon. By placing this concept at the tendon-bone interface, BioWick™ offers surgeons an entirely new option for patients with rotator cuff tears.

"BioWick’s design attempts to address the large biological rotator cuff issue without changing the surgical technique or increasing O.R. time for rotator cuff repair," states Joseph Abboud, MD, of The Rothman Institute in Philadelphia.

"The revolutionary design has changed the way I think about improving the problem at the tendon bone interface rather than utilizing allograft/xenograft tissues to potentially support this process on the bursal surface of the tendon."

Cayenne Medical, Inc. received 510(k) clearance from the Food and Drug Administration (FDA) for the BioWick SureLock Implant in July 2015. The implant is commercially available in the United States.